New Three-Drug cocktail targets Hard-to-Treat bladder cancer
NCT ID NCT05335941
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of three drugs—pemetrexed, etrumadenant, and zimberelimab—in 10 people with advanced bladder cancer that has a specific genetic change (MTAP deficiency) and has already been treated with immunotherapy. The goal is to see if the combo is safe and can shrink tumors. It is a small, early study at one cancer center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pemetrexed, etrumadenant, and zimberelimab
What this could lead to
If successful, this could offer a new treatment option for people with a specific type of advanced bladder cancer that has stopped responding to standard therapy.
What could go wrong
This is a very small, early-phase trial with only 10 participants at one center. The combination may cause significant side effects and may not prove effective in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States